Donald Gravenor

595 total citations
24 papers, 433 citations indexed

About

Donald Gravenor is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Donald Gravenor has authored 24 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Hematology. Recurrent topics in Donald Gravenor's work include Multiple Myeloma Research and Treatments (8 papers), Lung Cancer Research Studies (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Donald Gravenor is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Lung Cancer Research Studies (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Donald Gravenor collaborates with scholars based in United States, Germany and South Korea. Donald Gravenor's co-authors include Donald Woytowitz, Mohammed Al-Adhami, Gary Albert, Christian Manegold, J. Mezger, Vera Hirsh, Cynthia G. Leichman, Arthur Μ. Krieg, David Readett and James R. Berenson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Donald Gravenor

23 papers receiving 426 citations

Peers

Countries citing papers authored by Donald Gravenor

Since Specialization

Citations

This map shows the geographic impact of Donald Gravenor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Gravenor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Gravenor more than expected).

Fields of papers citing papers by Donald Gravenor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald Gravenor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Gravenor. The network helps show where Donald Gravenor may publish in the future.

Co-authorship network of co-authors of Donald Gravenor

This figure shows the co-authorship network connecting the top 25 collaborators of Donald Gravenor. A scholar is included among the top collaborators of Donald Gravenor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald Gravenor. Donald Gravenor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. 2025 ·Journal of Clinical Oncology ·(unknown), Vasily N. Aushev, Joe Ensor, Stephanie Sanchez, (unknown), Timothy Lewis Cannon, Lyudmyla Berim, Trevor Feinstein, Axel Grothey, (unknown), Sujith Kalmadi, Ahmed Zakari, (unknown), Donald Gravenor, Minetta C. Liu, Adham Jurdi, Alexey Aleshin, (unknown), Saima Sharif, Scott Kopetz	2
2	Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study. 2024 ·Journal of Clinical Oncology ·Pashtoon Murtaza Kasi, Vasily N. Aushev, Joe Ensor, (unknown), (unknown), Timothy Lewis Cannon, Lyudmyla Berim, Trevor Feinstein, Axel Grothey, (unknown), Sujith Kalmadi, Ahmed Zakari, Farshid Dayyani, Donald Gravenor, (unknown), Saima Sharif, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Scott Kopetz	37
3	Clinical, operative, and pathologic outcomes following neoadjuvant therapy versus upfront surgery for ampullary, duodenal and distal bile duct adenocarcinoma 2021 ·HPB ·(unknown), (unknown), Donald Gravenor, (unknown), (unknown), A.E. Bell, James R. Cantrell, Jeffrey J. Kovalic, Andrew S. Wright, (unknown), Gretchen Frantz, Arnel Pallera, (unknown), R.B. Yates, (unknown), (unknown), (unknown), Stephen W. Behrman	1
4	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial 2019 ·Journal for ImmunoTherapy of Cancer ·Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois, Manish R. Patel, Donald Gravenor, John Nemunaitis, Matthew H. Taylor, Lucjan Wyrwicz, Keun‐Wook Lee, Vijay Kasturi, Kevin M. Chin, Anja von Heydebreck, James L. Gulley	71
5	Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy 2014 ·Leukemia ·James R. Berenson, James Hilger, Ori Yellin, Robert Dichmann, Dipti Patel‐Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert Vescio	55
6	Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM). 2013 ·Journal of Clinical Oncology ·James R. Berenson, James Hilger, Robert Dichmann, Dipti Patel‐Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, (unknown), Youram Nassir, Regina A. Swift, Robert Vescio	2
7	Abstract P1-14-14: Neoadjuvant Sunitinib (S) Administered with Weekly Paclitaxel (P)/Carboplatin(C) in Patients (Pts) with Locally Advanced Triple-Negative Breast Cancer (TNBC): Preliminary Results from a Phase I/II Trial of the Sarah Cannon Research Institute. 2012 ·Cancer Research ·DA Yardley, (unknown), Carolyn B. Hendricks, Charles Webb, Victor Priego, (unknown), Donald Gravenor, Mythili Shastry, Tobias Chirwa, (unknown)	1
8	Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma 2012 ·British Journal of Haematology ·James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald Gravenor, Dipti Patel‐Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward J. Gorak, Youram Nassir, Regina A. Swift, (unknown)	39
9	Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI). 2012 ·Journal of Clinical Oncology ·Dianna Shipley, John D. Hainsworth, Tarek Mekhail, (unknown), (unknown), Davey B. Daniel, David Waterhouse, Donald Gravenor, Howard A. Burris, Frank A. Greco, David R. Spigel	1
10	A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen 2012 ·Blood ·James R. Berenson, James Hilger, Robert Dichmann, Dipti Patel‐Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert Vescio	1
11	A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance 2011 ·Clinical Lymphoma Myeloma & Leukemia ·James R. Berenson, Ori Yellin, Albert Quiery, (unknown), Ravi Patel, Siu‐Fun Wong, (unknown), Donald Gravenor, (unknown), (unknown), (unknown), (unknown), (unknown)	2
12	Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study 2011 ·Blood ·James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald Gravenor, Dipti Patel‐Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward J. Gorak, Regina A. Swift, (unknown)	2
13	Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid 2010 ·American Journal of Hematology ·James R. Berenson, Ori Yellin, John Crowley, Adel Makary, Donald Gravenor, Hank H. Yang, (unknown), Ian W. Flinn, Harry Staszewski, (unknown), (unknown), Charles M. Farber, Neil Morganstein, Vanessa Bolejack, Youram Nassir, James Hilger, (unknown), (unknown), Regina A. Swift	15
14	An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma 2010 ·Blood ·James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Donald Gravenor, Stephen J. Noga, Robert S. Siegel, Regina A. Swift, (unknown), Debra M. Bensen-Kennedy	0
15	Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer 2008 ·Journal of Clinical Oncology ·Christian Manegold, Donald Gravenor, Donald Woytowitz, J. Mezger, Vera Hirsh, Gary Albert, Mohammed Al-Adhami, David Readett, Arthur Μ. Krieg, Cynthia G. Leichman	129
16	Clinical and Radiologic Resolution of IgG 4 Normal, Nonoperatively Diagnosed Lymphoplasmacytic Sclerosing Pancreatitis (LPSP) after Initiation of Steroid Therapy 2007 ·Journal of Gastrointestinal Surgery ·Stephen W. Behrman, (unknown), Donald Gravenor	1
17	CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study 2005 ·Journal of Clinical Oncology ·(unknown), Donald Gravenor, Donald Woytowitz, J. Mezger, Gary Albert, Tess Schmalbach, Mohammed Al-Adhami, C. Manegold	17
18	PD-046 Phase II randomized trial adding a toll-like receptor 9 agonist (ProMuneTM) to first line chemotherapy shows improved response in advanced non-small cell lung cancer 2005 ·Lung Cancer ·C. Manegold, (unknown), Donald Gravenor, Donald Woytowitz, J. Mezger, (unknown), Mohammed Al-Adhami, Tess Schmalbach, John K. Whisnant	1
19	Tricyclic Antidepressant Agranulocytosis 1986 ·The Canadian Journal of Psychiatry ·Donald Gravenor, (unknown), (unknown)	4
20	5α-Androstane-3α, 17β-Diol: Inhibitor of Sexual Maturation in the Female Rat 1981 ·Biology of Reproduction ·I. Kraulis, (unknown), Donald Gravenor, K. B. Ruf	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact